Skip to main content

Advertisement

SpringerLink
Log in

Low-density lipoprotein in the setting of congestive heart failure: Is lower really better?

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Hypercholesterolemia is a risk factor for coronary artery disease (CAD), CAD mortality, and incident heart failure (HF). Lipid-lowering therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has been shown to reduce the risk of developing HF in patients with CAD. However, in patients with chronic established HF, hypercholesterolemia has not been associated with an increased risk of mortality. Several studies have demonstrated that higher lipid and lipoprotein levels, including total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides, are associated with significantly improved outcomes in HF of both ischemic and nonischemic etiologies. In light of the association between high cholesterol levels and improved survival in HF, statin or other lipid-lowering therapy in HF remains controversial. To date, large outcome trials of statin therapy in HF of multiple etiologies have not demonstrated mortality benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart Disease and Stroke Statistics-2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21–e181

    Article  PubMed  Google Scholar 

  2. Pekkanen J, Linn S, Heiss G, et al.: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990, 322:1700–1707.

    PubMed  CAS  Google Scholar 

  3. He J, Ogden LG, Bazzano LA, et al.: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161:996–1002.

    Article  PubMed  CAS  Google Scholar 

  4. Levy D, Larson MG, Vasan RS, et al.: The progression from hypertension to congestive heart failure. JAMA 1996, 275:1557–1562.

    Article  PubMed  CAS  Google Scholar 

  5. Adams JK, Fonarow GC, Emerman CL, et al.: Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209–216.

    Article  PubMed  Google Scholar 

  6. Schocken DD, Benjamin EJ, Fonarow GC, et al.: Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008, 117:2544–2565.

    Article  PubMed  Google Scholar 

  7. Kannel WB, Belanger AJ: Epidemiology of heart failure. Am Heart J 1991, 121(3 Pt 1):951–957.

    Article  Google Scholar 

  8. Kjekshus J, Pedersen TR, Olsson AG, et al.: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997, 3:249–254.

    Article  PubMed  CAS  Google Scholar 

  9. Pedersen TR: Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol 1998, 82:53T–56T.

    Article  PubMed  CAS  Google Scholar 

  10. Scirica BM, Morrow DA, Cannon CP, et al.: Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006, 47:2326–2331.

    Article  PubMed  CAS  Google Scholar 

  11. Vredevoe DL, Woo MA, Doering LV, et al.: Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1998, 82:323–328.

    Article  PubMed  CAS  Google Scholar 

  12. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC: Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002, 8:216–224.

    Article  PubMed  CAS  Google Scholar 

  13. Rauchhaus M, Koloczek V, Volk HD, et al.: Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000, 76:125–133.

    Article  PubMed  CAS  Google Scholar 

  14. Rauchhaus M, Clark AL, Doehner W, et al.: The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003, 42:1933–1940.

    Article  PubMed  CAS  Google Scholar 

  15. Afsarmanesh N, Horwich TB, Fonarow GC: Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J 2006, 152:1077–1083.

    Article  PubMed  CAS  Google Scholar 

  16. Horwich TB, Hernandez AF, Dai D, et al.: Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008, 156:1170–1176.

    Article  PubMed  CAS  Google Scholar 

  17. Christ M, Klima T, Grimm W, et al.: Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2006, 27:691–699.

    Article  PubMed  CAS  Google Scholar 

  18. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004, 43:1439–1444.

    Article  PubMed  Google Scholar 

  19. Horwich TB, Fonarow GC: Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial 2007, 20:549–553.

    Article  PubMed  Google Scholar 

  20. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC: Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008, 155:883–889.

    Article  PubMed  CAS  Google Scholar 

  21. Anker SD, Ponikowski P, Varney S, et al.: Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997, 349:1050–1053.

    Article  PubMed  CAS  Google Scholar 

  22. Deswal A, Petersen NJ, Feldman AM, et al.: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103:2055–2059.

    PubMed  CAS  Google Scholar 

  23. May HT, Muhlestein JB, Carlquist JF, et al.: Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol 2006, 98:653–658.

    Article  PubMed  CAS  Google Scholar 

  24. Rauchhaus M, Coats AJ, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 2000, 356:930–933.

    Article  PubMed  CAS  Google Scholar 

  25. Strey CH, Young JM, Molyneux SL, et al.: Endotheliumameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005, 179:201–206.

    Article  PubMed  CAS  Google Scholar 

  26. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712–1719.

    Article  PubMed  CAS  Google Scholar 

  27. Uretsky BF, Thygesen K, Armstrong PW, et al.: Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000, 102:611–616.

    PubMed  CAS  Google Scholar 

  28. Gao L, Wang W, Li YL, et al.: Simvastatin therapy normalizes sympathetic neural control in experimental heart failure. roles of angiotensin ii type 1 receptors and NAD(P)H oxidase. Circulation 2005, 112:1763–1770

    Article  PubMed  CAS  Google Scholar 

  29. Patel R, Nagueh SF, Tsybouleva N, et al.: Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001, 104:317–324.

    Article  PubMed  CAS  Google Scholar 

  30. Horwich TB, MacLellan WR, Fonarow GC: Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004, 43:642–648.

    Article  PubMed  CAS  Google Scholar 

  31. Go AS, Lee WY, Yang J, et al.: Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006, 296:2105–2111.

    Article  PubMed  CAS  Google Scholar 

  32. Ray JG, Gong Y, Sykora K, Tu JV: Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005, 165:62–67.

    Article  PubMed  CAS  Google Scholar 

  33. Fukuta H, Sane DC, Brucks S, Little WC: statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005, 112:357–363.

    Article  PubMed  CAS  Google Scholar 

  34. Node K, Fujita M, Kitakaze M, et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839–843.

    Article  PubMed  CAS  Google Scholar 

  35. Sola S, Mir MQ, Lerakis S, et al.: Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006, 47:332–337.

    Article  PubMed  CAS  Google Scholar 

  36. Bleske BE, Nicklas JM, Bard RL, et al.: Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006, 47:338–341.

    Article  PubMed  CAS  Google Scholar 

  37. Krum H, Ashton E, Reid C, et al.: Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, proinflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007, 13:1–7.

    Article  PubMed  CAS  Google Scholar 

  38. Kjekshus J, Apetrei E, Barrios V, et al.: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248–2261.

    Article  PubMed  CAS  Google Scholar 

  39. GISSI-HF Investigators, Tavazzi L, Maggioni AP, et al.: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231–1239.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, University of California, Los Angeles, 10833 Le Conte Avenue, CHS A2-237, Los Angeles, CA, 90095, USA

    Tamara Horwich

Authors
  1. Tamara Horwich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tamara Horwich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horwich, T. Low-density lipoprotein in the setting of congestive heart failure: Is lower really better?. Curr Atheroscler Rep 11, 343–349 (2009). https://doi.org/10.1007/s11883-009-0052-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-009-0052-4

Keywords

Search

Navigation